Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment

por Okusaka, Takuji, Otsuka, Taiga, Ueno, Hideki, Mitsunaga, Shuichi, Sugimoto, Rie, Muro, Kei, Saito, Isao, Tadayasu, Yusuke, Inoue, Kohei, Loembé, Arsene‐Bienvenu, Ikeda, Masafumi
Publicado 2016

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

por Kwon, Minsuk, Kim, Gahyun, Kim, Ryul, Kim, Kyu-Tae, Kim, Seung Tae, Smith, Simon, Mortimer, Peter G S, Hong, Jung Yong, Loembé, Arsene-Bienvenu, Irurzun-Arana, Itziar, Koulai, Loumpiana, Kim, Kyoung-Mee, Kang, Won Ki, Dean, Emma, Park, Woong-Yang, Lee, Jeeyun
Publicado 2022

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

por Kim, Seung Tae, Smith, Simon A., Mortimer, Peter, Loembé, Arsene-Bienvenu, Cho, Heejin, Kim, Kyoung-Mee, Smith, Claire, Willis, Sophie, Irurzun-Arana, Itziar, Berges, Alienor, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kozarewa, Iwanka, Pierce, Andrew J., Dean, Emma, Lee, Jeeyun
Publicado 2021